TN2012000057A1 - Antibodies against the ectodomain of erbb3 and uses thereof - Google Patents

Antibodies against the ectodomain of erbb3 and uses thereof

Info

Publication number
TN2012000057A1
TN2012000057A1 TNP2012000057A TN2012000057A TN2012000057A1 TN 2012000057 A1 TN2012000057 A1 TN 2012000057A1 TN P2012000057 A TNP2012000057 A TN P2012000057A TN 2012000057 A TN2012000057 A TN 2012000057A TN 2012000057 A1 TN2012000057 A1 TN 2012000057A1
Authority
TN
Tunisia
Prior art keywords
erbb3
antibodies
receptor
antigen binding
binding fragments
Prior art date
Application number
TNP2012000057A
Inventor
Birgit Schoeberl
Ulrik Nielsen
Michael Feldhaus
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2012000057(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of TN2012000057A1 publication Critical patent/TN2012000057A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3.
TNP2012000057A 2009-08-21 2012-02-09 Antibodies against the ectodomain of erbb3 and uses thereof TN2012000057A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21
PCT/US2010/046364 WO2011022727A2 (en) 2009-08-21 2010-08-23 Antibodies against the ectodomain of erbb3 and uses thereof

Publications (1)

Publication Number Publication Date
TN2012000057A1 true TN2012000057A1 (en) 2013-09-19

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2012000057A TN2012000057A1 (en) 2009-08-21 2012-02-09 Antibodies against the ectodomain of erbb3 and uses thereof

Country Status (21)

Country Link
EP (1) EP2467164A2 (en)
JP (1) JP5752687B2 (en)
KR (1) KR20120059568A (en)
CN (1) CN103002912A (en)
AU (1) AU2010284018C1 (en)
BR (1) BR112012003809A2 (en)
CA (1) CA2771744A1 (en)
CR (1) CR20120108A (en)
DO (1) DOP2012000044A (en)
EA (1) EA201200195A1 (en)
EC (1) ECSP12011740A (en)
IL (1) IL218097A0 (en)
IN (1) IN2012DN01518A (en)
MA (1) MA33582B1 (en)
MX (1) MX336091B (en)
NI (1) NI201200027A (en)
PE (1) PE20121585A1 (en)
SG (1) SG178509A1 (en)
TN (1) TN2012000057A1 (en)
WO (1) WO2011022727A2 (en)
ZA (1) ZA201201195B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2129396T1 (en) 2007-02-16 2013-12-31 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
EP2719708B1 (en) * 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing HER-3 associated diseases
HUE029026T2 (en) 2009-12-22 2017-01-30 Roche Glycart Ag ANTI-HER3 Antibodies and uses thereof
EA201201186A1 (en) 2010-03-11 2013-11-29 Мерримак Фармасьютикалс, Инк. USE OF ERBB3 INHIBITORS IN THE TREATMENT OF NEGATIVE AND BASAL-LIKE BREAST CANCER TREATMENT
BR112012025730B1 (en) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc isolated antibody that binds to human erbb3, its uses, its production process and expression vector
EA036314B1 (en) 2010-08-20 2020-10-26 Новартис Аг Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
IT1402149B1 (en) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma USE OF A PHOSPHOPEPTIDE WHICH IS ABLE TO BLOCK THE HER3 / P85 INTERACTION FOR THE TREATMENT OF HER2 EXPRESSION TUMORS.
WO2012059858A1 (en) * 2010-11-01 2012-05-10 Symphogen A/S Anti-her3 antibodies and compositions
CA2833643A1 (en) 2011-04-19 2012-10-26 Merrimack Pharmaceuticals, Inc. Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
CN103781800A (en) 2011-06-20 2014-05-07 协和发酵麒麟株式会社 Anti-erbB3 antibody
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
MX357391B (en) 2011-09-30 2018-07-06 Regeneron Pharma Anti-erbb3 antibodies and uses thereof.
WO2013052745A1 (en) 2011-10-06 2013-04-11 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-erbb3 antibodies
US9637543B2 (en) 2011-11-09 2017-05-02 The Uab Research Foundation HER3 antibodies and uses thereof
EA036739B1 (en) 2011-12-05 2020-12-15 Новартис Аг Antibodies for epidermal growth factor receptor 3 (her3)
US20150037336A1 (en) * 2012-02-22 2015-02-05 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US20160232293A1 (en) * 2013-10-17 2016-08-11 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10844127B2 (en) 2014-02-28 2020-11-24 Merus N.V. Antibodies that bind EGFR and ErbB3
CN105367657B (en) * 2014-08-14 2019-09-13 上海生物制品研究所有限责任公司 Anti- HER3 antibody, its preparation method and its application
US10526416B2 (en) 2014-09-08 2020-01-07 Yeda Research And Development Co. Ltd. Anti-HER3 antibodies and uses of same
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
MX2018004988A (en) 2015-10-23 2018-11-09 Merus Nv Binding molecules that inhibit cancer growth.
BR112019020508A2 (en) 2017-03-31 2020-08-04 Merus N.V. bispecific antibodies binding to erbb-2 and erbb3 for use in the treatment of cells that have an nrg1 fusion gene
EP3665200A4 (en) 2017-08-09 2021-04-28 University of Saskatchewan Her3 binding agents and uses thereof
JP2020530028A (en) 2017-08-09 2020-10-15 メルス ナムローゼ フェンノートシャップ Antibodies that bind to EGFR and cMET
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
US20210246223A1 (en) * 2018-06-22 2021-08-12 Crd Pharmaceuticals Inc ANTI-HER3 Antibody and uses thereof
AU2021360625A1 (en) * 2020-10-14 2023-06-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof
WO2023198138A1 (en) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 Antibody or antigen-binding fragment thereof and medical use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2129396T1 (en) * 2007-02-16 2013-12-31 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof

Also Published As

Publication number Publication date
CN103002912A (en) 2013-03-27
SG178509A1 (en) 2012-04-27
KR20120059568A (en) 2012-06-08
IN2012DN01518A (en) 2015-06-05
EP2467164A2 (en) 2012-06-27
NI201200027A (en) 2013-01-29
WO2011022727A2 (en) 2011-02-24
BR112012003809A2 (en) 2019-09-24
AU2010284018B2 (en) 2014-06-05
AU2010284018C1 (en) 2015-10-15
ECSP12011740A (en) 2013-02-28
JP5752687B2 (en) 2015-07-22
DOP2012000044A (en) 2012-06-30
CR20120108A (en) 2012-06-05
EA201200195A1 (en) 2012-12-28
JP2013506622A (en) 2013-02-28
AU2010284018A1 (en) 2012-03-22
CA2771744A1 (en) 2011-02-24
MX2012002172A (en) 2012-05-29
IL218097A0 (en) 2012-04-30
MA33582B1 (en) 2012-09-01
ZA201201195B (en) 2015-07-29
MX336091B (en) 2016-01-08
PE20121585A1 (en) 2012-11-29
WO2011022727A3 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
TN2012000057A1 (en) Antibodies against the ectodomain of erbb3 and uses thereof
MX2009008656A (en) Antibodies against erbb3 and uses thereof.
PH12019501115A1 (en) Anti-cd134 (ox40) antibodies and uses thereof
MX350957B (en) Binding molecules specific for her3 and uses thereof.
PH12015500390A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
MX2015006548A (en) Binding proteins comprising at least two repeat domains against her2.
TN2015000124A1 (en) Compositions and methods for antibodies targeting epo
WO2013184912A3 (en) Binding agents that modulate the hippo pathway and uses thereof
EP2560684A4 (en) Fibronectin type iii domain-based multimeric scaffolds
MX2012007340A (en) Anti-her3 antibodies and uses thereof.
MX2013004897A (en) Anti-her3 antibodies and compositions.
WO2012058592A3 (en) Non-antagonistic egfr-binding molecules and immunoconjugates thereof
EP3461847A8 (en) Humanized antibodies to liv-1 and use of same to treat cancer
MD20150102A2 (en) Humanized anti-CD134 (OX40) antibodies and uses thereof
MX347515B (en) Frizzled-binding agents and uses thereof.
CY1119154T1 (en) ANTI-VLA-4 ANTIBODIES
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
EP2579895A4 (en) Anti-vegf antibodies and uses thereof
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
UA106529C2 (en) Humanized antibodies to cxcr4 for cancer treatment
IN2014DN09717A (en)
IN2014CN04374A (en)
MX2015005756A (en) Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and the beta-hairpin of her4.
WO2015048008A3 (en) Binding molecules specific for her3 and uses thereof
PH12019500677A1 (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof